| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/02656730701824406 |
| P698 | PubMed publication ID | 18214773 |
| P50 | author | Olav Dahl | Q16188074 |
| Øystein Fluge | Q73922036 | ||
| Erling Dahl Borkamo | Q125330488 | ||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia | Q24599829 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer | Q28248186 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Drug penetration in solid tumours | Q29614404 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Molecular regulation of angiogenesis and lymphangiogenesis | Q29616150 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Regulation of angiogenesis by hypoxia: role of the HIF system | Q29619187 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 | ||
| Imaging of angiogenesis: from microscope to clinic | Q31144032 | ||
| Development of matrix metalloproteinase inhibitors in cancer therapy. | Q31832006 | ||
| Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. | Q31929753 | ||
| Study of non-uniform nanoparticle liposome extravasation in tumour | Q33219519 | ||
| Introduction: non-invasive thermometry for thermotherapy | Q33222929 | ||
| A 76-year-old man with macular degeneration. | Q33244419 | ||
| Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents | Q33245795 | ||
| Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery | Q33263624 | ||
| Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma | Q33266043 | ||
| Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor | Q33941495 | ||
| FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer | Q34004891 | ||
| Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling | Q34078666 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma | Q34272640 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Renal-cell carcinoma--molecular pathways and therapies. | Q55042930 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| Renal-Cell Carcinoma | Q56019528 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria | Q57571506 | ||
| Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology | Q57618588 | ||
| Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma | Q57618625 | ||
| A Very Effective Treatment for Neovascular Macular Degeneration | Q57784664 | ||
| VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group | Q57904831 | ||
| Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase | Q58023953 | ||
| Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia | Q58455732 | ||
| Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis | Q80203516 | ||
| Cervical cancer: radiotherapy and hyperthermia | Q36497622 | ||
| High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy. | Q36497626 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Predicting benefit from anti-angiogenic agents in malignancy | Q36534760 | ||
| Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer | Q36593165 | ||
| Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment | Q36609698 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| Therapy for metastatic colorectal cancer | Q36618823 | ||
| The multifaceted circulating endothelial cell in cancer: towards marker and target identification. | Q36621435 | ||
| Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Q36628049 | ||
| Eosinophilic leukaemia | Q36795143 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| Vascular damaging agents | Q36801914 | ||
| Hyperthermia: a potent enhancer of radiotherapy. | Q36817620 | ||
| Rituximab therapy in malignant lymphoma | Q36832102 | ||
| Trastuzumab: triumphs and tribulations | Q36832109 | ||
| Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. | Q36832116 | ||
| Bevacizumab in the treatment of non-small-cell lung cancer | Q36832129 | ||
| HER2-positive breast cancer: current and future treatment strategies | Q36839672 | ||
| Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas | Q36869621 | ||
| Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors | Q36883658 | ||
| Dermatofibrosarcoma protuberans: recent clinical progress | Q36890069 | ||
| A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia | Q36892617 | ||
| Bevacizumab in non small cell lung cancer | Q36899890 | ||
| Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer | Q37201832 | ||
| Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 | ||
| Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro | Q37352738 | ||
| EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms | Q38314949 | ||
| Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects | Q38464708 | ||
| Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors | Q40144623 | ||
| Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia | Q40171279 | ||
| Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer | Q40253380 | ||
| Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy | Q40271356 | ||
| ROS production and angiogenic regulation by macrophages in response to heat therapy | Q40271384 | ||
| Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). | Q40493215 | ||
| Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours | Q40593312 | ||
| Endothelial cells and hyperthermia | Q40635169 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors | Q43430750 | ||
| Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q43565576 | ||
| Researchers optimistic about sea change in cancer treatment | Q43636680 | ||
| Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors | Q43663314 | ||
| CHOP plus rituximab--balancing facts and opinion | Q43864042 | ||
| Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat | Q43930195 | ||
| Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders | Q44265479 | ||
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 | ||
| Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas | Q44867750 | ||
| Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer | Q44912086 | ||
| Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. | Q44942124 | ||
| Vinca alkaloids: anti-vascular effects in a murine tumour | Q46555781 | ||
| Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab | Q46666366 | ||
| Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials | Q46735180 | ||
| Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib | Q46735182 | ||
| Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype | Q48784777 | ||
| Reliability of temperature and SAR measurements at oesophageal tumour locations. | Q51110049 | ||
| Hyperthermia mediated liposomal drug delivery. | Q51186669 | ||
| Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures. | Q51918803 | ||
| Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. | Q52925886 | ||
| Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. | Q52931245 | ||
| Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. | Q52932508 | ||
| Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system. | Q52936795 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. | Q53271595 | ||
| Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor. | Q54309824 | ||
| Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. | Q54573260 | ||
| HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 | ||
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Q34551403 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Comparing antibody and small-molecule therapies for cancer | Q34560075 | ||
| Mechanisms of cutaneous toxicities to EGFR inhibitors. | Q34567916 | ||
| Sunitinib in patients with metastatic renal cell carcinoma | Q34568166 | ||
| Metronomic scheduling: the future of chemotherapy? | Q34569946 | ||
| The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration | Q34571631 | ||
| Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer | Q34624378 | ||
| BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia | Q34651708 | ||
| Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. | Q34744991 | ||
| Hyperthermia in combined treatment of cancer | Q34766163 | ||
| Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? | Q34988256 | ||
| Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer | Q35172774 | ||
| Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences | Q35177652 | ||
| The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. | Q35740647 | ||
| Monoclonal antibodies as therapeutic agents for cancer | Q35761687 | ||
| Characterizing the tumor response to treatment with combretastatin A4 phosphate | Q35793182 | ||
| Vascular-targeting therapies for treatment of malignant disease. | Q35805639 | ||
| Effects of hyperthermia on the peripheral nervous system: a review. | Q35809599 | ||
| The role of gefitinib in lung cancer treatment. | Q35817512 | ||
| Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma | Q35943769 | ||
| Imaging angiogenesis: applications and potential for drug development | Q36027611 | ||
| Systemic therapy for colorectal cancer | Q36029007 | ||
| Angiogenic inhibitors: a new therapeutic strategy in oncology | Q36306264 | ||
| Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment | Q36336662 | ||
| Re-setting the biologic rationale for thermal therapy | Q36336673 | ||
| Lymphangiogenesis in development and human disease | Q36342355 | ||
| Advances in oral therapy for multiple myeloma. | Q36436240 | ||
| Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). | Q36442804 | ||
| Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. | Q36497610 | ||
| Tissue physiology and the response to heat. | Q36497614 | ||
| Hyperthermia and gene therapy: potential use of microPET imaging | Q36497619 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 97-110 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | International Journal of Hyperthermia | Q332272 |
| P1476 | title | Current status of antivascular therapy and targeted treatment in the clinic | |
| P478 | volume | 24 |
Search more.